New pill aims to control iron overload in genetic disorder
NCT ID NCT07371793
First seen Feb 01, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This early-stage trial tests an oral drug called BBI-001 for hereditary hemochromatosis, a condition causing too much iron in the body. The study has two parts: one with healthy volunteers to check safety, and another with patients to see how the drug affects iron levels. Participants take the drug or a placebo three times daily for up to 14 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMOCHROMATOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Unit
Sydney, New South Wales, 2031, Australia
Contact
Conditions
Explore the condition pages connected to this study.